TrialJournal of hematology & oncology2012

A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide.

Eunice S Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.